JPRN-UMIN000004573已完成2 期
Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer - Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer
First Department of Internal Medicine, Shinshu University School of Medicine0 个研究点目标入组 42 人开始时间: 2010年11月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Previously treated with paclitaxel and / or bevacizumab 2) Patients with brain metastasis 3) Patients with hemoptysis 4) Patients receiving therapeutic anticoagulation 5) Patients with complications like below Active infection Acute myocardial infarction during recent 6 months or the other severe heart disease Uncontrollable diabetes mellitus Uncontrollable hypertension Active psychological disease 6) Hypersensitivity to paclitaxel and / or bevacizumab 7) Active concomitant malignancy 8) Pregnancy or lactation 9) Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
2 期
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.HER2-negative metastatic breast cancerJPRN-UMIN000015971Sairtama Breast Cancer Clinical Study Group (SBCCSG)51
撤回
不适用
Phase II trial of pembrolizumab and paclitaxel in hormone receptor-positive, hyperMUTATted metastatic breast cancer Identified by whole exOme sequeNcing (‘MUTATION2’)NeoplasmsKCT0005975Yonsei University Health System, Severance Hospital52
进行中（未招募）
1 期
Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcomaEUCTR2016-002464-14-ESGrupo Español de Investigación en Sarcomas (GEIS)61
已完成
2 期
Phase II Trial of Bevacizumab in Combination with XELOX in Colorectal Cancer Patients with Liver Metastases (H2, H3)colorectal liver metastasesJPRN-UMIN000002897iigata Colorectal cancer Chemotherapy Study Group (NCCSG)20
已完成
2 期
Phase II trial of the addition of bevacizumab to alectinib beyond progressive disease in ALK-positive advanced non-small-cell lung cancer.ALK-positive non-small cell lung cancerJPRN-UMIN000017828iigata Lung Cancer Treatment Group11